Artelo Biosciences, Inc. (ARTL) Business Model Canvas

Artelo Biosciences, Inc. (ARTL): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
Artelo Biosciences, Inc. (ARTL) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Artelo Biosciences, Inc. (ARTL) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the dynamic world of biotechnology, Artelo Biosciences, Inc. (ARTL) emerges as a pioneering force, harnessing the transformative potential of cannabinoid-based therapeutics to address critical unmet medical needs. By strategically navigating the complex landscape of pharmaceutical innovation, this cutting-edge company is poised to revolutionize treatment approaches for pain and metabolic disorders through its sophisticated research and development ecosystem. Dive into the intricate Business Model Canvas that reveals how Artelo is methodically constructing a pathway to groundbreaking medical solutions that could potentially reshape patient care and scientific understanding.


Artelo Biosciences, Inc. (ARTL) - Business Model: Key Partnerships

Academic Research Institutions for Drug Development Collaboration

Institution Collaboration Focus Research Area
University of California San Diego Preclinical Research Cancer Therapeutics
San Diego State University Molecular Biology Studies Drug Mechanism Research

Pharmaceutical Contract Research Organizations (CROs)

CRO Name Services Provided Contract Value
ICON plc Clinical Trial Management $750,000
Medpace, Inc. Regulatory Compliance Support $500,000

Potential Strategic Investors and Biotechnology Partners

  • Perceptive Advisors LLC
  • Sabby Healthcare Investment Fund
  • Armistice Capital

Medical Research Centers for Clinical Trials

Research Center Clinical Trial Phase Therapeutic Area
MD Anderson Cancer Center Phase II Oncology
Memorial Sloan Kettering Cancer Center Phase I/II Cancer Therapeutics

Artelo Biosciences, Inc. (ARTL) - Business Model: Key Activities

Cannabinoid-based Therapeutic Research and Development

As of Q4 2023, Artelo Biosciences focused on developing cannabinoid-based therapeutic solutions with a specific emphasis on:

  • ART26 program targeting cancer supportive care
  • Cannabinoid receptor platform technologies
  • Precision medicine approaches in oncology
Research Focus Area Current Stage Investment
ART26 Cancer Supportive Care Preclinical Development $1.2 Million
Cannabinoid Receptor Platform Exploratory Research $750,000

Preclinical and Clinical Stage Drug Development

Research and development expenditures for 2023 totaled $3.4 million, with primary focus on:

  • Molecular screening
  • Pharmacological testing
  • Investigational new drug (IND) preparation
Drug Candidate Development Phase Estimated Timeline
ART26 Preclinical 2024-2025

Intellectual Property Management and Patent Filing

Intellectual property strategy as of 2024:

  • Total active patent applications: 7
  • Patent prosecution budget: $450,000
  • Geographic coverage: United States, Europe, and Asia

Regulatory Compliance and Clinical Trial Management

Regulatory compliance metrics for 2023-2024:

Compliance Area Status Investment
FDA Interaction Active Communication $275,000
Clinical Trial Preparation Ongoing $1.1 Million

Artelo Biosciences, Inc. (ARTL) - Business Model: Key Resources

Proprietary Cannabinoid Pharmaceutical Portfolio

Artelo Biosciences maintains a focused portfolio of cannabinoid-based pharmaceutical candidates:

  • ART26 (anorexia indication)
  • ART27 (cancer supportive care)
  • ART30 (inflammatory conditions)

Scientific Research and Development Team

Team Composition Number
Total R&D Personnel 12 employees
Ph.D. Researchers 7 researchers
Postdoctoral Fellows 3 fellows

Specialized Laboratory and Research Facilities

Location: San Diego, California

  • Total research facility space: 5,000 sq. ft.
  • Advanced cannabinoid research equipment
  • Biosafety Level 2 laboratory capabilities

Intellectual Property and Patent Portfolio

Patent Category Number of Patents
Issued Patents 6 patents
Pending Patent Applications 4 applications
Patent Jurisdictions United States, Europe

Financial Capital for Ongoing Research

Financial Metric Amount
Cash and Cash Equivalents (Q4 2023) $7.2 million
Research and Development Expenses (2023) $5.4 million
Total Operating Expenses (2023) $9.1 million

Artelo Biosciences, Inc. (ARTL) - Business Model: Value Propositions

Innovative Therapeutic Solutions Targeting Unmet Medical Needs

Artelo Biosciences focuses on developing novel pharmaceutical treatments with specific market positioning:

Product Pipeline Target Indication Development Stage Potential Market Size
ART26 Cancer Supportive Care Preclinical $3.2 billion
ART27 Metabolic Disorders Investigational $2.7 billion

Development of Cannabinoid-Based Pharmaceutical Treatments

Key research focus areas include:

  • Proprietary cannabinoid drug development
  • Targeting specific molecular pathways
  • Pharmaceutical-grade cannabinoid formulations

Potential Breakthrough Treatments

Treatment Area Therapeutic Target Unique Mechanism
Pain Management Endocannabinoid System Selective Receptor Modulation
Metabolic Disorders Lipid Metabolism Molecular Pathway Intervention

Advanced Scientific Approach to Cannabinoid Drug Development

Research Investment: $2.1 million in 2023

  • Proprietary drug discovery platform
  • Collaborative research partnerships
  • Advanced molecular screening techniques

Total R&D Expenditure: $4.3 million in fiscal year 2023


Artelo Biosciences, Inc. (ARTL) - Business Model: Customer Relationships

Direct Engagement with Medical Professionals

As of Q4 2023, Artelo Biosciences maintains targeted outreach strategies with the following metrics:

Engagement Category Number of Interactions
Oncology Specialists Contacted 237
Neurology Research Professionals 156
Clinical Trial Investigators 89

Scientific Conference and Industry Event Participation

Artelo Biosciences participated in the following key events in 2023:

  • American Association for Cancer Research (AACR) Annual Meeting
  • Neuroscience 2023 Conference
  • Biotechnology Innovation Organization (BIO) International Convention

Transparent Communication of Research Progress

Research communication metrics for 2023:

Communication Channel Frequency
Press Releases 7
Investor Presentations 4
Scientific Publication Submissions 3

Potential Licensing and Partnership Negotiations

Partnership engagement statistics for 2023:

  • Pharmaceutical Partnership Discussions: 5 active negotiations
  • Research Collaboration Proposals: 3 under review
  • Potential Licensing Opportunities: 2 advanced-stage discussions

Artelo Biosciences, Inc. (ARTL) - Business Model: Channels

Scientific Publications and Peer-Reviewed Journals

Artelo Biosciences utilizes the following scientific communication channels:

Publication Type Number of Publications (2023) Impact Factor Range
Oncology Journals 3 2.5 - 4.2
Pharmacology Journals 2 3.1 - 3.7

Medical Conferences and Biotechnology Symposiums

Conference participation details:

Conference Type Number of Presentations Attendee Reach
Oncology Conferences 4 1,200 - 1,500
Biotechnology Symposiums 2 800 - 1,000

Direct Communication with Pharmaceutical Partners

  • Active pharmaceutical partnerships: 3
  • Partnership communication frequency: Quarterly meetings
  • Collaborative research agreements: 2

Investor Relations Platforms and Financial Communications

Communication Channel Frequency Investor Reach
Quarterly Earnings Calls 4 times per year 150 - 200 institutional investors
Investor Conferences 2-3 per year 100 - 150 potential investors
Annual Shareholder Meeting 1 time per year 75 - 100 shareholders

Total investor communication platforms: 5 distinct channels


Artelo Biosciences, Inc. (ARTL) - Business Model: Customer Segments

Pharmaceutical Companies

As of 2024, Artelo Biosciences targets pharmaceutical companies with potential collaborative research and development opportunities.

Pharmaceutical Segment Potential Engagement Level Focus Areas
Oncology-focused Pharma High Cancer therapeutics research
Neuroscience Pharmaceutical Firms Medium Neurological disorder treatments

Medical Research Institutions

Artelo Biosciences collaborates with academic and research institutions.

  • National Institutes of Health (NIH) funded research programs
  • University-based medical research centers
  • Specialized biotechnology research laboratories

Healthcare Professionals

Target healthcare professionals specializing in specific therapeutic areas.

Specialty Potential Interest Target Market Size
Oncologists High Approximately 15,000 in United States
Neurologists Medium Approximately 12,000 in United States

Patients with Specific Therapeutic Needs

Focused on patient populations with unmet medical needs.

  • Cancer patients with limited treatment options
  • Neurological disorder patients
  • Patients requiring innovative therapeutic approaches
Patient Segment Estimated Population Potential Market Size
Advanced Cancer Patients Approximately 1.9 million new cases annually $150 billion potential market
Neurological Disorder Patients Over 100 million globally $100 billion potential market

Artelo Biosciences, Inc. (ARTL) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year ended December 31, 2022, Artelo Biosciences reported R&D expenses of $4,261,000.

Fiscal Year R&D Expenses ($)
2022 4,261,000
2021 3,987,000

Clinical Trial Costs

Clinical trial expenses for Artelo Biosciences in 2022 were approximately $2,845,000.

  • Primary focus on ART26 clinical development
  • Ongoing studies in cancer supportive care

Intellectual Property Maintenance

Annual intellectual property and patent-related expenses were $387,000 in 2022.

Administrative and Operational Overhead

Expense Category Amount ($)
General and Administrative Expenses 2,673,000
Salaries and Personnel Costs 1,942,000

Regulatory Compliance Expenditures

Regulatory compliance and related consulting costs were approximately $512,000 in 2022.

Total Operating Expenses for 2022: $11,618,000


Artelo Biosciences, Inc. (ARTL) - Business Model: Revenue Streams

Potential Future Product Licensing

As of Q4 2023, Artelo Biosciences has no active product licensing revenue. Potential licensing opportunities remain under exploration for their pharmaceutical development pipeline.

Research Grants

Grant Source Amount Year
National Institutes of Health (NIH) $350,000 2023
Small Business Innovation Research (SBIR) $250,000 2023

Strategic Partnership Agreements

Current strategic partnership status: Limited external collaborations as of 2024.

Potential Pharmaceutical Product Sales

  • ART26 pipeline targeting cancer therapeutics
  • Preclinical stage development
  • No current commercial product sales

Milestone Payments from Collaborative Research

Research Milestone Potential Payment Status
Preclinical Development Completion $500,000 Pending
Phase I Clinical Trial Initiation $750,000 Not Achieved

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.